119 related articles for article (PubMed ID: 36523200)
21. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
Kienbaum P; Scherbaum N; Thürauf N; Michel MC; Gastpar M; Peters J
Crit Care Med; 2000 Apr; 28(4):969-76. PubMed ID: 10809268
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
23. Patterns of naloxone use in hospitalized patients.
Yung L; Lee KC; Hsu C; Furnish T; Atayee RS
Postgrad Med; 2017 Jan; 129(1):40-45. PubMed ID: 27858510
[TBL] [Abstract][Full Text] [Related]
24. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
[TBL] [Abstract][Full Text] [Related]
25. Reversal of Opioid-Induced Ventilatory Depression Using Low-Dose Naloxone (0.04 mg): a Case Series.
Kim HK; Nelson LS
J Med Toxicol; 2016 Mar; 12(1):107-10. PubMed ID: 26289651
[TBL] [Abstract][Full Text] [Related]
26. Development and evaluation of a pilot overdose education and naloxone distribution program for hospitalized general medical patients.
Jakubowski A; Pappas A; Isaacsohn L; Castillo F; Masyukova M; Silvera R; Holaday L; Rausch E; Farooq S; Veltri KT; Cunningham CO; Bachhuber MA
Subst Abus; 2019; 40(1):61-65. PubMed ID: 30475162
[No Abstract] [Full Text] [Related]
27. Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice.
Madison CA; Arora M; Kumar MNVR; Eitan S
ACS Chem Neurosci; 2020 Jul; 11(13):1955-1964. PubMed ID: 32491828
[TBL] [Abstract][Full Text] [Related]
28. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD
Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382
[TBL] [Abstract][Full Text] [Related]
29. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate.
Gan TJ; Ginsberg B; Glass PS; Fortney J; Jhaveri R; Perno R
Anesthesiology; 1997 Nov; 87(5):1075-81. PubMed ID: 9366459
[TBL] [Abstract][Full Text] [Related]
30. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.
Eissenberg T; Johnson RE; Bigelow GE; Walsh SL; Liebson IA; Strain EC; Stitzer ML
Drug Alcohol Depend; 1997 Apr; 45(1-2):81-91. PubMed ID: 9179510
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine.
Pinelli A; Trivulzio S
J Pharmacol Toxicol Methods; 1997 Nov; 38(3):117-31. PubMed ID: 9523765
[TBL] [Abstract][Full Text] [Related]
33. Dispensing a Naloxone Kit at Hospital Discharge: A Retrospective QI Project.
Train MK; Patel N; Thapa K; Pasho M; Acquisto NM
Am J Nurs; 2020 Dec; 120(12):48-52. PubMed ID: 33214374
[TBL] [Abstract][Full Text] [Related]
34. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
Alcaraz C; Vargas ML; Milanés MV
Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296
[TBL] [Abstract][Full Text] [Related]
35. Incidence of Naloxone Redosing in the Age of the New Opioid Epidemic.
Klebacher R; Harris MI; Ariyaprakai N; Tagore A; Robbins V; Dudley LS; Bauter R; Koneru S; Hill RD; Wasserman E; Shanes A; Merlin MA
Prehosp Emerg Care; 2017; 21(6):682-687. PubMed ID: 28686547
[TBL] [Abstract][Full Text] [Related]
36. Conditioning processes contribute to severity of naloxone-precipitated withdrawal from acute opioid dependence.
Schulteis G; Morse AC; Liu J
Psychopharmacology (Berl); 2004 Oct; 175(4):463-72. PubMed ID: 15083263
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review of Naloxone Dosing and Adverse Events in the Emergency Department.
Yugar B; McManus K; Ramdin C; Nelson LS; Parris MA
J Emerg Med; 2023 Sep; 65(3):e188-e198. PubMed ID: 37652808
[TBL] [Abstract][Full Text] [Related]
38. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
Kohan LR; Elmofty D; Pena I; Liao C
J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
[TBL] [Abstract][Full Text] [Related]
39. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.
Lewanowitsch T; Irvine RJ
Eur J Pharmacol; 2002 Jun; 445(1-2):61-7. PubMed ID: 12065195
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
